Categories Earnings, Health Care
Earnings Summary: Highlights of HCA Healthcare’s Q4 2024 financial results
Hospital chain HCA Healthcare, Inc. (NYSE: HCA) on Friday announced financial and operating results for the fourth quarter of fiscal 2024.
- Fourth-quarter revenues increased to $18.29 billion from $17.3 billion in the comparable quarter a year earlier
- Net income attributable to the company was $1.44 billion or $5.63 per share in Q4, vs. $1.61 billion or $5.93 per share last year
- Adjusted EBITDA totaled $3.71 billion in the December quarter, compared to $3.62 billion in Q4 2023
- Cash flows from operating activities came in at $2.56 billion in the fourth quarter
- Same-facility admissions increased by 3% and same-facility equivalent admissions rose by 3.1%
- The company declared a quarterly dividend of $0.72 per share, to be paid on March 31, 2025, to stockholders of record on March 17, 2025
- For fiscal 2025, the management expects revenues to be in the range of $72.80 billion to $75.80 billion
- The forecast for full-year net Income is in the $5.85 -$6.29 billion range; EPS is expected to be between $24.05 and $25.85 in FY25
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Infographic: Amazon (AMZN) Q4 2024 earnings beat estimates; sales rise 10%
E-commerce giant Amazon.com Inc. (NASDAQ: AMZN) on Thursday reported higher sales and profit for the fourth quarter of 2024. Earnings also beat analysts' estimates. Net sales increased to $187.8 billion
Philip Morris (PM) delivers strong performance in 4Q24 helped by smoke-free strength
Shares of Philip Morris International Inc. (NYSE: PM) jumped 10% on Thursday after the company delivered better-than-expected earnings results for the fourth quarter of 2024 and provided an encouraging outlook
Highlights of Bristol-Myers Squibb’s Q4 2024 earnings report
Biotechnology company Bristol Myers Squibb (NYSE: BMY) reported lower profit for the fourth quarter of 2024, despite an increase in revenue. Net income attributable to shareholders was $72 million or